Ocular Therapeutix (NASDAQ:OCUL) Insider Peter Kaiser Sells 2,967 Shares

Ocular Therapeutix, Inc. (NASDAQ:OCUL) insider Peter Kaiser sold 2,967 shares of the company’s stock in a transaction that occurred on Tuesday, May 26th. The shares were sold at an average price of $8.20, for a total value of $24,329.40. Following the transaction, the insider owned 266,141 shares of the company’s stock, valued at approximately $2,182,356.20. This represents a 1.10% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Ocular Therapeutix Price Performance

Shares of Ocular Therapeutix stock opened at $9.15 on Friday. The company has a quick ratio of 14.73, a current ratio of 14.81 and a debt-to-equity ratio of 0.12. The company has a market cap of $2.00 billion, a PE ratio of -6.27 and a beta of 0.93. The business has a 50 day moving average of $8.79 and a 200 day moving average of $10.23. Ocular Therapeutix, Inc. has a 52 week low of $6.23 and a 52 week high of $16.44.

Institutional Investors Weigh In On Ocular Therapeutix

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. NewEdge Advisors LLC grew its stake in Ocular Therapeutix by 1,274.6% in the first quarter. NewEdge Advisors LLC now owns 13,746 shares of the biopharmaceutical company’s stock worth $116,000 after purchasing an additional 12,746 shares during the period. California State Teachers Retirement System grew its stake in shares of Ocular Therapeutix by 41.8% in the first quarter. California State Teachers Retirement System now owns 213,706 shares of the biopharmaceutical company’s stock worth $1,810,000 after acquiring an additional 63,005 shares during the last quarter. Readystate Asset Management LP purchased a new stake in shares of Ocular Therapeutix in the first quarter worth $7,484,000. Royal Bank of Canada grew its stake in shares of Ocular Therapeutix by 175.1% in the first quarter. Royal Bank of Canada now owns 26,554 shares of the biopharmaceutical company’s stock worth $225,000 after acquiring an additional 16,902 shares during the last quarter. Finally, Rock Springs Capital Management LP grew its stake in shares of Ocular Therapeutix by 11.0% in the first quarter. Rock Springs Capital Management LP now owns 383,716 shares of the biopharmaceutical company’s stock worth $3,250,000 after acquiring an additional 37,896 shares during the last quarter. 59.21% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of equities analysts recently commented on OCUL shares. Jefferies Financial Group restated a “buy” rating on shares of Ocular Therapeutix in a report on Tuesday, February 17th. HC Wainwright reaffirmed a “buy” rating and issued a $21.00 price target on shares of Ocular Therapeutix in a research note on Monday, April 13th. Wall Street Zen cut Ocular Therapeutix from a “hold” rating to a “sell” rating in a research note on Saturday, February 28th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Ocular Therapeutix in a research note on Tuesday, April 21st. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $18.00 price target on shares of Ocular Therapeutix in a research note on Tuesday, May 5th. Twelve analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $23.78.

Ocular Therapeutix Company Profile

Ocular Therapeutix, Inc is a biopharmaceutical company dedicated to the development of innovative therapies for diseases and conditions of the eye. Founded in 2011 and headquartered in Bedford, Massachusetts, the company focuses on sustained-release drug delivery platforms designed to address key unmet needs in ophthalmology. Its proprietary hydrogel-based inserts and sealants aim to improve patient compliance and outcomes by providing controlled release of active pharmaceutical ingredients directly to ocular tissues.

The company’s flagship product, DEXTENZA®, is a preservative-free, sustained-release dexamethasone intracanalicular insert approved by the U.S.